- ISIN
- US1421521071
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jun 18, 2025
Highlights
- Market Cap
- $4.67B
- Enterprise Value
- $3.85B
- EPS (TTM)
- $0.05
- PE Ratio
- 307.22
- PEG Ratio
- 1.17
- Total Revenue (TTM)
- $907.29M
- Gross Profit (TTM)
- $482.11M
- EBITDA (TTM)
- $92.24M
- Year Range
- $14.19 - $42.50
- Target Price
- $28.75
- ROA (TTM)
- 2.92%
- ROE (TTM)
- 5.73%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
CAI Performance Chart
Caris Life Sciences, Inc (CAI) is down 38.8% since the beginning of the year. At $17 per share, CAI is trading 61.1% below its 52-week high of $43.
Loading charts...
Returns By Period
Caris Life Sciences, Inc
- 1D
- 0.43%
- 1M
- -11.61%
- YTD
- -38.77%
- 6M
- -39.35%
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.68%
- YTD
- 11.16%
- 6M
- 11.10%
- 1Y
- 27.46%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
CAI Monthly Returns History
Based on dividend-adjusted daily data since Jun 18, 2025, CAI's average daily return is -0.14%, while the average monthly return is -3.03%.
Historically, 31% of months were positive and 69% were negative. The best month was Aug 2025 with a return of +36.7%, while the worst month was Sep 2025 at -21.2%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.
On a daily basis, CAI closed higher 47% of trading days. The best single day was Aug 21, 2025 with a return of +8.7%, while the worst single day was May 8, 2026 at -18.6%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.16% | -13.04% | -11.22% | 6.26% | -12.00% | -1.20% | -38.77% | ||||||
| 2025 | -4.57% | 5.09% | 36.72% | -21.20% | -0.56% | -15.13% | 5.68% | -3.64% |
Benchmark Metrics
Caris Life Sciences, Inc has an annualized alpha of -53.10%, beta of 1.52, and R2 of 0.09 versus S&P 500 Index. Calculated based on daily prices since June 20, 2025.
- This stock participated in 255.36% of S&P 500 Index downside but only -73.67% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.09 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -53.10%
- Beta
- 1.52
- R²
- 0.09
- Upside Capture
- -73.67%
- Downside Capture
- 255.36%
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Caris Life Sciences, Inc (CAI) and compare them to S&P 500 Index.
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Caris Life Sciences, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Caris Life Sciences, Inc was 62.98%, occurring on May 15, 2026. The portfolio has not yet recovered.
The current Caris Life Sciences, Inc drawdown is 57.96%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -62.98%May 2026 | 8mo 23d | — | 9mo 13dAug 2025 - now |
2025 correction2025 | -13.82%Jul 2025 | 11d | 15d | 26dJul 2025 - Aug 2025 |
2025 selloff2025 | -7.36%Jun 2025 | 3d | 22d | 25dJun 2025 - Jul 2025 |
2025 pullback2025 | -5.19%Aug 2025 | 5d | 1d | 6dAug 2025 - Aug 2025 |
Drawdown Indicators
| CAI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.98% | -56.78% | -6.20% |
Max Drawdown (1Y)Largest decline over 1 year | — | -9.10% | — |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -57.96% | 0.00% | -57.96% |
Average DrawdownAverage peak-to-trough decline | -30.93% | -10.72% | -20.21% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | — | 1.97% | — |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Caris Life Sciences, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Caris Life Sciences, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for CAI, comparing it with other companies in the Biotechnology industry. Currently, CAI has a P/E ratio of 307.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for CAI compared to other companies in the Biotechnology industry. CAI currently has a PEG ratio of 1.2. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CAI relative to other companies in the Biotechnology industry. Currently, CAI has a P/S ratio of 11.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CAI in comparison with other companies in the Biotechnology industry. Currently, CAI has a P/B value of 7.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with CAI
Add Caris Life Sciences, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with CAI